Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2019

01.11.2018 | Original Article

Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function

verfasst von: Martin Freesmeyer, Falk Gühne, Christian Kühnel, Thomas Opfermann, Thomas Winkens, Anke Werner

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Renal function and effective half-life (t1/2,eff) of I-131 have not been fully elucidated in patients undergoing radioiodine therapy (RAIT) for differentiated thyroid cancer (DTC). Aim of the present analysis was to evaluate the potential of cystatin C-based estimated glomerular filtration rate (eGFRCysC) in comparison to conventional creatinine (eGFRCrea) and to verify which methods to determine t1/2,eff are most accurate to predict t1/2,eff.

Methods

Forty-eight patients receiving whole-body I-131-scintigraphy were included. eGFRCysC was compared to eGFRCrea with regard to accuracy of t1/2,eff prediction. Three different methods (i.e. blood-based, gamma camera-based and probe-based) and two protocols with either three (short period,SP; up to 42 h) or four (long period,LP; up to 114 h) time points were compared using the Akaike’s information criterion.

Results

The eGFRCysC measurement is more likely than eGFRCrea in predicting the t1/2,eff. High correlation coefficients were found between t1/2,eff assessed by gamma camera and probe measurements and blood-based determination revealed lower values. Patients with normal eGFR showed higher values of t1/2,eff of LP compared to SP.

Conclusions

eGFRCysC should be included in further study protocols. As camera and probe measurements lead to almost superimposable results, one of the methods is expendable. Blood-based results of t1/2,eff were lower, presumably due to unspecific iodine retention, whereas the lower correlation with renal function may be caused by individual differences in intestinal iodine resorption. SP-protocols up to 42 h after I-131 administration are sufficient to determine t1/2,eff. Further studies are necessary for specific recommendations regarding I-131 activity reduction during RAIT in patients with DTC and renal insufficiency.
Literatur
1.
M. Dietlein, W. Eschner, F. Grunwald, M. Lassmann, F. Verburg, M. Luster, Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Nuklearmedizin 55, 77–89 (2016). Version 4CrossRefPubMed
2.
M. Luster, S.E. Clarke, M. Dietlein, M. Lassmann, P. Lind, W. Oyen, J. Tennvall, E. Bombardieri, Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941–1959 (2008)CrossRefPubMed
3.
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral
4.
R.R. Cavalieri, Iodine metabolism and thyroid physiology: current concepts. Thyroid 7, 177–181 (1997)CrossRefPubMed
5.
C. Alevizaki, M. Molfetas, A. Samartzis, B. Vlassopoulou, C. Vassilopulos, P. Rondogianni, S. Kottou, V. Hadjiconstantinou, M. Alevizaki, Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones 5, 276–287 (2006)CrossRefPubMed
6.
M. Lassmann, H. Hanscheid, C. Chiesa, C. Hindorf, C. Flux, M. Luster, EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 35, 1405–1412 (2008)CrossRefPubMed
7.
K. Vogel, T. Opfermann, S. Wiegand, J. Biemann, M. Busch, T. Winkens, M. Freesmeyer, Relationship between estimated glomerular filtration rate and biological half-life of 131I. Retrospective analysis in patients with differentiated thyroid carcinoma. Nuklearmedizin 52, 164–169 (2013)CrossRefPubMed
8.
A.S. Levey, L.A. Stevens, C.H. Schmid, Y.P. Zhang, A.F. Castro, H.I. Feldman, J.W. Kusek, P. Eggers, F. van Lente, T. Greene, J. Coresh, A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009)CrossRefPubMedPubMedCentral
9.
L.A. Inker, C.H. Schmid, H. Tighiouart, J.H. Eckfeldt, H.I. Feldman, T. Greene, J.W. Kusek, J. Manzi, F. van Lente, Y.P. Zhang, J. Coresh, A.S. Levey, Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367, 20–29 (2012)CrossRefPubMedPubMedCentral
10.
A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, M.W. Steffes, R.J. Hogg, R.D. Perrone, J. Lau, G. Eknoyan, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139, 137–147 (2003)CrossRefPubMed
11.
12.
S.F. Barrington, A.G. Kettle, M.J. O’Doherty, C.P. Wells, E.J.R. Somer, A.J. Coakley, Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur. J. Nucl. Med. 23, 123–130 (1996)CrossRefPubMed
13.
T. Smith, C.J. Edmonds, A slow component of iodine turnover in athyreotic individuals. Clin. Sci. Mol. Med. 53, 81–86 (1977)PubMed
14.
Y. Sakamoto, M. Ishiguro, G. Kitagawa, Akaike information criterion statistics. Tokyo (u.a.): KTK Scient. Publ.; 1986
15.
K.P. Burnham, D.R. Anderson, K.P. Huyvaert, AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons. Behav. Ecol. Sociobiol. 65, 23–35 (2011)CrossRef
16.
H. Hanscheid, M. Lassmann, M. Luster, S.R. Thomas, F. Pacini, C. Ceccarelli, P.W. Ladenson, R.L. Wahl, M. Schlumberger, M. Ricard, A. Driedger, R.T. Kloos, S.I. Sherman, B.R. Haugen, V. Carriere, C. Corone, C. Reiners, Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 47, 648–654 (2006)PubMed
17.
H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, M. Ricard, 131I effective half-life and dosimetry in thyroid cancer patients. J. Nucl. Med. 49, 1445–1450 (2008)CrossRefPubMed
18.
C. Menzel, W.T. Kranert, N. Dobert, M. Diehl, T. Fietz, N. Hamscho, U. Berner, F. Grunwald, rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J. Nucl. Med. 44, 1065–1068 (2003)PubMed
19.
M. Luster, S.I. Sherman, M.C. Skarulis, J.R. Reynolds, M. Lassmann, H. Hanscheid, C. Reiners, Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 30, 1371–1377 (2003)CrossRefPubMed
20.
F. Pacini, P.W. Ladenson, M. Schlumberger, A. Drieder, M. Luster, R.T. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, R. Elisei, C. Ceccarelli, A. Pinchera, R.L. Wahl, S. Leoulleux, M. Ricard, J. Yoo, N.L. Busaidy, E. Delpassand, H. Hanscheid, R. Felbinger, M. Lassmann, Cl Reiners, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926–932 (2006)CrossRefPubMed
21.
F. Duranton, A. Lacoste, P. Faurous, E. Deshayes, J. Ribstein, A. Avignon, G. Mourad, A. Argiles, Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. Clin. Kidney J. 6, 478–483 (2013)CrossRefPubMedPubMedCentral
22.
G.B. Coura-Filho, J. Willegaignon, C.A. Buchpiguel, M.T. Sapienza, Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer. Thyroid 25, 1291–1296 (2015)CrossRefPubMed
23.
S.J. Lee, H.Y. Lee, W.W. Lee, S.E. Kim, The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy. Nucl. Med. Commun. 35, 727–732 (2014)CrossRefPubMed
24.
D. Taieb, F. Sebag, B. Farman-Ara, T. Portal, K. Baumstarck-Barrau, C. Fortanier, M. Bourrelly, J. Mancini, C. De Micco, P. Auquier, B. Conte-Devolx, J.F. Henry, O. Mundler, Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 95, 3283–3290 (2010)CrossRefPubMed
25.
J. Halstenberg, W.T. Kranert, H. Korkusuz, A. Mayer, H. Ackermann, F. Grunwald, C. Happel, Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves’ disease. Nuklearmedizin 57, 43–49 (2018)CrossRefPubMed
26.
J. Willegaignon, R.A. Pelissoni, B.C. Lima, M.T. Sapienza, G.B. Coura, C.A. Buchpiguel, Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine. Nucl. Med. Commun. 37, 473–479 (2016)CrossRefPubMed
27.
R. Hojs, S. Bevc, R. Ekart, M. Gorenjak, L. Puklavec, Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin. Nephrol. 70, 10–17 (2008)CrossRefPubMed
28.
M.T. Keddis, H. Amer, N. Voskoboev, W.K. Kremers, A.D. Rule, J.C. Lieske, Creatinine-Based, G.F.R. Cystatin C-Based, Estimating equations and their non-GFR determinants in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 11, 1640–1649 (2016)CrossRefPubMedPubMedCentral
29.
L.A. Stevens, C.H. Schmid, T. Greene, L. Li, G.J. Beck, M.M. Joffe, M. Froissart, J.W. Kusek, Y.P. Zhang, J. Coresh, A.S. Levey, Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 75, 652–660 (2009)CrossRefPubMed
30.
D.S. Riggs, Quantitative aspects of iodine metabolism in man. Pharmacol. Rev. 4, 284–370 (1952)PubMed
31.
R.D. Perrone, N.E. Madias, A.S. Levey, Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 38, 1933–1953 (1992)PubMed
32.
E. Randers, E.J. Erlandsen, Serum cystatin C as an endogenous marker of the renal function--a review. Clin. Chem. Lab. Med. 37, 389–395 (1999)CrossRefPubMed
33.
34.
D.C. Brater, Measurement of renal function during drug development. Br. J. Clin. Pharmacol. 54, 87–95 (2002)CrossRefPubMed
35.
H.S. Lee, H. Rhee, E.Y. Seong, D.W. Lee, S.B. Lee, I.S. Kwak, Comparison of glomerular filtration rates calculated by different serum cystatin C-based equations in patients with chronic kidney disease. Kidney Res. Clin. Pract. 33, 45–51 (2014)CrossRefPubMedPubMedCentral
36.
A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, S. Hendriksen, J.W. Kusek, F. Van Lente, Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145, 247–254 (2006)CrossRefPubMed
37.
D.W. Cockcroft, M.H. Gault, Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41 (1976)CrossRefPubMed
38.
J. Willegaignon, R.A. Pelissoni, B.C. Lima, M.T. Sapienza, G.B. Coura-Filho, M.A. Queiroz, C.A. Buchpiguel, Estimating (131)I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification. Radiol. Bras. 49, 150–157 (2016)CrossRefPubMedPubMedCentral
39.
L. Johansson, S. Leide-Svegborn, S. Mattsson, B. Nosslin, Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother. Radiopharm. 18, 445–450 (2003)CrossRefPubMed
40.
G.H. Kramer, B.M. Hauck, M.J. Chamberlain, Biological half-life of iodine in adults with intact thyroid function and in athyreotic persons. Radiat. Prot. Dosim. 102, 129–135 (2002)CrossRef
41.
N.R. Hill, S.T. Fatoba, J.L. Oke, J.A. Hirst, C.A. O’Callaghan, D.S. Lasserson, F.D.R. Hobbs, Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS ONE 11, e0158765 (2016)CrossRefPubMedPubMedCentral
Metadaten
Titel
Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function
verfasst von
Martin Freesmeyer
Falk Gühne
Christian Kühnel
Thomas Opfermann
Thomas Winkens
Anke Werner
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1800-4

Weitere Artikel der Ausgabe 3/2019

Endocrine 3/2019 Zur Ausgabe

Original Article

MIR4532 gene variant rs60432575 influences the expression of KCNJ11 and the sulfonylureas-stimulated insulin secretion

Original Article

Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women

Original Article

Maternal cinnamon intake during lactation led to visceral obesity and hepatic metabolic dysfunction in the adult male offspring

Original Article

The effects of sampling lateralization on bilateral inferior petrosal sinus sampling and desmopressin stimulation test for pediatric Cushing's disease

Original Article

Expression of the growth hormone receptor isoforms and its correlation with the metabolic profile in morbidly obese subjects

Endocrine Surgery

High prevalence of adrenal insufficiency at diagnosis and headache recovery in surgically resected Rathke’s cleft cysts—a large retrospective single center study

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise